In breast cancer cell lines, SUMOylation prevents FASN degradation by the proteasome, and the reduction in SUMOylation caused by SUMO2 silencing reduces the stability of FASN and inhibits the development of tumor cells (Floris et al., 2020). This evidence concerns the gene FASN and neoplasm.